Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
54
SVA Quote, Financials, Valuation and Earnings
Last price:
$6.47
Seasonality move
:
-2.1%
Day range:
$6.47 - $6.47
52-week range:
$6.47 - $6.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.50x
P/B ratio:
0.62x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$464.9M
Revenue:
$448.3M
EPS (TTM):
-$1.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -- | -- | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -- | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 17.43% | -30.7% | $43.42 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ASCLF
Ascletis Pharma, Inc.
|
$2.2550 | -- | $2.2B | -- | $0.00 | 0% | 6,719.85x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.77 | $4.00 | $15.7M | -- | $0.00 | 0% | 0.45x |
|
VBIZF
Viva Biotech Holdings
|
$0.3434 | -- | $724.5M | 19.39x | $0.00 | 0% | 3.15x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$10.42 | -- | $21.2B | 29.93x | $0.00 | 0% | 7.86x |
|
ZLAB
Zai Lab Ltd.
|
$20.04 | $43.42 | $2.2B | -- | $0.00 | 0% | 4.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.263 | 12.91% | 11.22x |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -8.397 | -- | 12.82x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | -0.389 | 55.28% | 0.19x |
|
VBIZF
Viva Biotech Holdings
|
24.82% | -7.949 | -- | 1.26x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | -0.126 | -- | 1.98x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.192 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ASCLF
Ascletis Pharma, Inc.
|
-- | -- | -13.95% | -13.95% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -1.17% | -1.8% | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Sinovac Biotech Ltd. vs. Competitors
-
Which has Higher Returns SVA or ASCLF?
Ascletis Pharma, Inc. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of --. Sinovac Biotech Ltd.'s return on equity of -1.05% beat Ascletis Pharma, Inc.'s return on equity of -13.95%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B ASCLFAscletis Pharma, Inc.-- -- $269.3M -
What do Analysts Say About SVA or ASCLF?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Ascletis Pharma, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sinovac Biotech Ltd. has higher upside potential than Ascletis Pharma, Inc., analysts believe Sinovac Biotech Ltd. is more attractive than Ascletis Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 ASCLFAscletis Pharma, Inc.0 0 0 -
Is SVA or ASCLF More Risky?
Sinovac Biotech Ltd. has a beta of 0.746, which suggesting that the stock is 25.394% less volatile than S&P 500. In comparison Ascletis Pharma, Inc. has a beta of -19.220, suggesting its less volatile than the S&P 500 by 2022.009%.
-
Which is a Better Dividend Stock SVA or ASCLF?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. Ascletis Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. Ascletis Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or ASCLF?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than Ascletis Pharma, Inc. quarterly revenues of --. Sinovac Biotech Ltd.'s net income of -- is lower than Ascletis Pharma, Inc.'s net income of --. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while Ascletis Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 6,719.85x for Ascletis Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- ASCLFAscletis Pharma, Inc.6,719.85x -- -- --
-
Which has Higher Returns SVA or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of -353.92%. Sinovac Biotech Ltd.'s return on equity of -1.05% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About SVA or CASI?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 422.81%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is SVA or CASI More Risky?
Sinovac Biotech Ltd. has a beta of 0.746, which suggesting that the stock is 25.394% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.412%.
-
Which is a Better Dividend Stock SVA or CASI?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or CASI?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Sinovac Biotech Ltd.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 0.45x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- CASICASI Pharmaceuticals, Inc.0.45x -- $3.1M -$10.9M
-
Which has Higher Returns SVA or VBIZF?
Viva Biotech Holdings has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of --. Sinovac Biotech Ltd.'s return on equity of -1.05% beat Viva Biotech Holdings's return on equity of -1.8%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B VBIZFViva Biotech Holdings-- -- $694.7M -
What do Analysts Say About SVA or VBIZF?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Viva Biotech Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Sinovac Biotech Ltd. has higher upside potential than Viva Biotech Holdings, analysts believe Sinovac Biotech Ltd. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 VBIZFViva Biotech Holdings0 0 0 -
Is SVA or VBIZF More Risky?
Sinovac Biotech Ltd. has a beta of 0.746, which suggesting that the stock is 25.394% less volatile than S&P 500. In comparison Viva Biotech Holdings has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.774%.
-
Which is a Better Dividend Stock SVA or VBIZF?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. Viva Biotech Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. Viva Biotech Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or VBIZF?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than Viva Biotech Holdings quarterly revenues of --. Sinovac Biotech Ltd.'s net income of -- is lower than Viva Biotech Holdings's net income of --. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while Viva Biotech Holdings's PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 3.15x for Viva Biotech Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- VBIZFViva Biotech Holdings3.15x 19.39x -- --
-
Which has Higher Returns SVA or WXXWY?
WuXi Biologics (Cayman), Inc. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of --. Sinovac Biotech Ltd.'s return on equity of -1.05% beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B -
What do Analysts Say About SVA or WXXWY?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sinovac Biotech Ltd. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Sinovac Biotech Ltd. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 WXXWYWuXi Biologics (Cayman), Inc.0 0 0 -
Is SVA or WXXWY More Risky?
Sinovac Biotech Ltd. has a beta of 0.746, which suggesting that the stock is 25.394% less volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of -0.062, suggesting its less volatile than the S&P 500 by 106.225%.
-
Which is a Better Dividend Stock SVA or WXXWY?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or WXXWY?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than WuXi Biologics (Cayman), Inc. quarterly revenues of --. Sinovac Biotech Ltd.'s net income of -- is lower than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while WuXi Biologics (Cayman), Inc.'s PE ratio is 29.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 7.86x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- WXXWYWuXi Biologics (Cayman), Inc.7.86x 29.93x -- --
-
Which has Higher Returns SVA or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of -30.98%. Sinovac Biotech Ltd.'s return on equity of -1.05% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About SVA or ZLAB?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $43.42 which suggests that it could grow by 116.67%. Given that Zai Lab Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Zai Lab Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is SVA or ZLAB More Risky?
Sinovac Biotech Ltd. has a beta of 0.746, which suggesting that the stock is 25.394% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.879, suggesting its less volatile than the S&P 500 by 12.141%.
-
Which is a Better Dividend Stock SVA or ZLAB?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or ZLAB?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Sinovac Biotech Ltd.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 4.87x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- ZLABZai Lab Ltd.4.87x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
